{
    "title": "Sage's depression drug improves symptoms, but durability concerns sink shares",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10519225/Sages-depression-drug-meets-main-goal-late-stage-study.html",
    "date": "2022-02-16",
    "keywords": [
        "drug",
        "effect",
        "zuranolone",
        "trial",
        "latestage",
        "study",
        "wednesday",
        "disorder",
        "improvement",
        "company",
        "biogen",
        "analyst",
        "june",
        "year",
        "sage",
        "suneja",
        "day",
        "depressive",
        "investor",
        "antidepressant",
        "period",
        "partner",
        "inc",
        "durability",
        "key",
        "success",
        "benefit",
        "joon",
        "process",
        "noise",
        "controversy",
        "symptom",
        "depression",
        "market",
        "approval",
        "deal",
        "reduction",
        "placebo",
        "difference",
        "street",
        "yatin",
        "time",
        "goal",
        "fifteen",
        "reporting",
        "daniel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}